Gut and immune function
LL-37
Editorial audit: October 15, 2026 · draft; scientific, medical and translation review pending
01What is reported
LL-37 is described for antimicrobial, biofilm and inflammatory aims, sometimes as a systemic component of a gut or immune combination.
02Proposed rationale
Host-defense biology motivates the claim, but a molecule’s antimicrobial activity in an experiment does not establish safe systemic treatment.
03What the research shows
A controlled topical leg-ulcer trial did not show overall benefit; exploratory findings in larger ulcers do not replace its main result.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
04Limits and unknowns
Topical research cannot establish injected antibiofilm efficacy. Site, concentration, formulation and exposure matter to both benefit and harm.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
05Questions to ask about the product
Is the cited study topical while the reported exposure is injected? Make the mismatch visible.
06Open research question
How frequently do community accounts preserve infection confirmation and the exact outcome, rather than infer “biofilm clearance” from nonspecific symptoms?
Primary and regulatory references
- 1.
- 2.